Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: A randomized double-blind trial

Journal of Hypertension

Volumn 20, Issue 4, 2002, Pages 729-737

  Ruilope, Luis M ^a   Fernandez R ^a   Rodriguez Perez J C ^a   Garcia de Vinuesa S ^a   Garrido, J ^a   Romero, R ^a   Jarillo, D ^a   Raij, L ^a   Alvarez Cantalapiedra, I ^a   Lazaro de Mercado Ma R ^a   Gomez Campdera F ^a   Jarillo Ibanez D ^a   Garcia Martin F ^a   Mora Macia J ^a   Nieto, J ^a   Vozmediano, C ^a   Hortal, L ^a   Plaza, C ^a   Aljama, P ^a   Gomez Carrasco J M ^a   Soriano, S ^a   Perez Garcia A ^a   Garces L ^a   Segura, J ^a   Bonet, J ^a   Vigil Medina, A ^a   Gallar, P ^a   Oliet, A ^a   Bernis, C ^a   Sanz Guajardo D ^a   more..

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Blood pressure; Primary renal disease; Proteinuria; Trandolapril; Verapamil

Indexed keywords

ATENOLOL; CALCIUM; SERUM ALBUMIN; TRANDOLAPRIL;

ADULT; ALBUMIN BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TITRIMETRY; TREATMENT OUTCOME;

EID: 0036528790     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200204000-00032     Document Type: Article

References (21)

1. The progression of chronic renal failure: A harmful quartet
2. Nephropatic nature of proteinuria
3. Blood pressure control, proteinuria and renal outcome in chronic renal failure
4. Progression rate to end-stage renal failure in non-diabetic kidney diseases: A multivariate analysis of determinant factors
5. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure
6. 1999 World Health Organization - International society of hypertension guidelines for the management of hypertension
7. Renal aspects of the Hypertension Optimal Treatment (HOT) Study
8. Effects of dihydropyridine calcium channel blockers, angiotensi-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropaties
9. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
10. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
11. Albumin excretion rate and metabolic modifications in patients with essential hypertension
12. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy
13. Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease
14. Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease
15. Randomised controlled trial of enalapril and β blockers in non-diabetic chronic renal failure
16. Antihypertensive treatment of patients with proteinuric renal diseases: Risks or benefits of calcium channel blockers?
17. Antiproteinuric effect of verapamil in comparison to trandolapril in non-diabetic renal disease
18. Effects of angiotensin converting enzyme inhibitors on the progression of renal failure and proteinuria in humans
19. Additive antiproteinuric effect of converting enzyme inhibition and a low protein intake
20. Efficacy and variability of the antiproteinuric effect of ACE inhibitor lisinopril
21. Is it wise to combine an ACE inhibitor and an angiotensin receptor antagonist?